A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)

British Journal of Haematology

Volumn 161, Issue 1, 2013, Pages 68-75

  Mascarenhas, John ^a   Lu, Min ^a   Li, Timmy ^a   Petersen, Bruce ^a   Hochman, Tsivia ^b   Najfeld, Vesna ^a   Goldberg, Judith D ^b   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epigenetics; Histone deacetylase inhibitor; Myelofibrosis; Panobinostat; Phase I

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; LOPERAMIDE; PANOBINOSTAT; PHENYLALANINE; PREDNISOLONE; THALIDOMIDE; VALINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING DISORDER; BLOATING; BONE PAIN; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS; POST POLYCYTHEMIA VERA RELATED MYELOFIBROSIS; PRIORITY JOURNAL; SIDE EFFECT; SPLENOMEGALY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGED; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SPLENOMEGALY; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84875032119     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12220     Document Type: Article

References (17)

1. Atadja, P. (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Letters, 280, 233-241.
2. Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A. & Tefferi, A. (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437-438.
3. Cervantes, F., Dupriez, B., Passamonti, F., Vannucchi, A.M., Morra, E., Reilly, J.T., Demory, J.L., Rumi, E., Guglielmelli, P., Roncoroni, E., Tefferi, A. & Pereira, A. (2012) Improving survival trends in primary myelofibrosis: an international study. Journal of Clinical Oncology, 30, 2981-2987.
4. De Angelo, D.J., Tefferi, A., Fiskus, W., Mesa, R.A., Paley, C.S., Wadleigh, M., Snyder, D.S., Begna, K., Ondovik, M.S., Rine, J. & Bhalla, K.N. (2010) A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood (ASH Annual Meeting Abstracts), 116, 630a.
5. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
6. Glaser, K.B. (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochemical Pharmacology, 74, 659-671.
7. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, R., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366, 787-798.
8. Najfeld, V., Tripodi, J., Scalise, A., Silverman, L.R., Silver, R.T., Fruchtman, S. & Hoffman, R. (2010) Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. British Journal of Haematology, 151, 288-291.
9. Quintas-Cardama, A., Kantarjian, H., Estrov, Z., Borthakur, G., Cortes, J. & Verstovsek, S. (2012) Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Research, 36, 1124-1127.
10. Rambaldi, A., Dellacasa, C.M., Finazzi, G., Carobbio, A., Ferrari, M.L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M.C., Di Tollo, S., D'Urzo, C., Vannucchi, G., Barosi, G. & Barbui, T. (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 150, 446-455.
11. + cells from patients with idiopathic myelofibrosis. Cancer Research, 67, 6417-6424.
12. Silverman, L.R., Fenaux, P., Mufti, G.J., Santini, V., Hellstrom-Lindberg, E., Gattermann, N., Sanz, G., List, A.F., Gore, S.D., Seymour, J.F., Backstrom, J., McKenzie, D. & Beach, C.L. (2008) The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update. Ecancermedicalscience, 2, 118.
13. Spencer, A., Prince, M., De Angelo, D.J., Fischer, T., Bhalla, K.N., Giles, F.J., Liu, A., Parker, K., Laird, G., Masson, E., Rediske, J., Scott, J.W. & Ottmann, O.G. (2007) Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts), 110, 907a.
14. Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, L.A., Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G. & Kantarjian, H. (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood, 108, 1497-1503.
15. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092-1097.
16. Verstovsek, S. (2011) Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. Journal of Clinical Oncology, 29, 781-783.
17. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., Di Persio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, Jr J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799-807.